Related Experiment Videos
Posttraumatic epilepsy with special emphasis on prophylaxis and prevention
1Neurosurgical Clinic University of Torino, Torino, Italy. carloapagni@virgilio.it
Acta Neurochirurgica. Supplement
|July 1, 2005
Summary
Controlling early posttraumatic epileptic seizures after head injury is crucial. While traditional antiepileptic drugs fail to prevent late seizures, experimental treatments targeting free radicals show promise for posttraumatic epilepsy prophylaxis.
Area of Science:
- Neuroscience
- Neurology
- Pharmacology
Background:
- Posttraumatic epileptic seizures occur in approximately 10% of severe head injury cases.
- Early seizures (within the first week) require immediate control to prevent secondary brain damage.
- Late seizures, occurring months or years post-injury, define the syndrome of posttraumatic epilepsy.
Purpose of the Study:
- To review the management of early posttraumatic seizures.
- To evaluate the efficacy of antiepileptic drug prophylaxis for preventing late posttraumatic seizures.
- To explore potential prophylactic strategies targeting the mechanisms of epileptogenesis.
Main Methods:
- Review of clinical series on severe head injuries and seizure incidence.
- Analysis of studies on antiepileptic drug efficacy in human posttraumatic epilepsy.
- Examination of experimental models, including iron-induced epilepsy, and potential prophylactic agents.
Main Results:
- Intravenous phenytoin effectively controls early seizures.
- Antiepileptic drugs (phenytoin, phenobarbital, carbamazepine, valproate) have failed in human prophylaxis, preventing seizures only during treatment.
- Experimental studies show prophylactic effects of free radical scavengers and antioxidants in animal models of posttraumatic epilepsy.
Conclusions:
- Current antiepileptic drugs do not offer permanent prophylaxis for posttraumatic epilepsy.
- The epileptogenic focus in posttraumatic epilepsy involves a cascade of events initiated by hemorrhage and iron liberation.
- Free radical scavengers and antioxidants represent a promising avenue for future posttraumatic epilepsy prophylaxis, though human studies are lacking.